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Abstract
Background: Atopic diseases constitute a major health chal-
lenge for industrialized countries, and elevated levels of in-
terleukin 4 (IL-4) frequently characterize these disorders. 
Previous in vitro analyses have indicated that IL-4 strongly 
upregulates the expression of IL-4-sensitive genes in human 
monocytes. Objective: To explore whether similar expres-
sion alterations may contribute to the pathomechanisms of 
atopic diseases in vivo we carried out a small-scale case-con-
trol clinical study (n = 43), in which we quantified the plasma 
levels of IgE and IL-4 as well as the expression of selected IL-
4-sensitive genes in blood leukocytes. Methods: 34 allergic 
patients suffering from allergic rhinitis (n = 11), atopic ecze-
ma (n = 11) and allergic asthma (n = 12) as well as 9 healthy 
control individuals were recruited. IgE and IL-4 plasma levels 
were determined by ELISA, and the expression of selected 
IL-4-sensitive gene products in blood leukocytes was quanti-
fied by qRT-PCR. In addition, the fatty acid oxygenase activ-
ity of isolated monocytes was measured by RP-HPLC analysis 
of the arachidonic acid oxygenation products (ex vivo activ-
ity assays). Results: We found that plasma levels of IgE and 
IL-4 were significantly elevated in atopic patients but the de-
gree of elevation was not sufficient to upregulate the expres-
sion of the selected IL-4-sensitive genes in circulating leuko-
cytes. Moreover, the arachidonic acid oxygenase activity of 
blood monocytes was not significantly altered in atopic pa-
tients. Conclusion: Our data suggest that the IL-4 plasma lev-
els of atopic patients are not high enough to impact the ex-
pression of IL-4-sensitive genes. © 2019 S. Karger AG, Basel
Introduction
Allergic diseases are among the most common chron-
ic disorders in all industrialized countries [1]. Their inci-
dence and prevalence have continuously been rising in 
recent years [2], and millions of people around the world 
are affected [3]. The chronic inflammatory processes as-
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sociated with allergic disorders, as e.g. atopic dermatitis, 
are even discussed to be linked to psychological comor-
bidities such as depression [4]. The pathomechanisms of 
allergic diseases are still unclear [5], and except for anti-
gen avoidance there is no causal therapy. Eicosanoids 
such as prostaglandins [6] and leukotrienes [7] have been 
implicated in the pathogenesis of allergic disorders, and 
inhibitors of leukotriene biosynthesis are currently avail-
able for prescription as antiasthmatic medication [8]. 
Atopic diseases, such as atopic rhinitis and atopic derma-
titis [9], involve a more or less severe dysregulation of the 
adaptive immune response, and frequently IgE blood lev-
els are elevated [10–12]. In severe cases anti-IgE treat-
ment is even used as therapeutic strategy [13]. Interleu-
kin-4 (IL-4) is a Th2 cytokine, which is secreted during 
atopic flares [14]. In healthy humans IL-4 plasma concen-
trations vary between 2 and 39 pg/mL [11, 15–18] but in 
one study even higher concentrations (> 450 pg/mL) were 
found [16]. For atopic patients conflicting data have been 
published [11, 16–19]. When human peripheral mono-
cytes are cultured in vitro in the presence of IL-4, the ex-
pression of a complex array of genes was altered [20]. The 
most strongly upregulated gene product (300-fold) was 
ALOX15 [20] but more recent studies suggested a parallel 
upregulation of ALOX15B expression [21]. Unfortunate-
ly, the in vivo relevance of this in vitro effect has never 
been investigated.
To fill this gap we here addressed the following ques-
tions: (i) Are IL-4 plasma levels elevated in atopic pa-
tients? (ii) Is the degree of elevation high enough to in-
duce expression of selected IL-4-sensitive genes? (iii) Is 
there a statistic correlation between the IL-4 plasma levels 
and the expression of these genes? (iv) Are the IL-4 levels 
of atopic patients sufficiently high to upregulate the fatty 
acid oxygenase activity of blood monocytes?
Materials and Methods
Study Design, Patients and Healthy Controls
The study was carried out as 2-phase clinical case-control trial 
at the Department of Dermatology and Allergology at the Chari-
té – Universitätsmedizin, Berlin. During the first phase circulating 
total IgE and IL-4 concentrations were determined in the plasma 
of atopic patients and of corresponding controls. Expression of 
ALOX isoforms and other IL-4-sensitive genes was quantified in 
peripheral leukocytes. During the second phase peripheral mono-
cytes were prepared from atopic patients and healthy controls, and 
their endogenous arachidonic acid oxygenase activities were eval-
uated. Patients were recruited from the patient pool of the clinic 
and underwent complete clinical evaluation including physical ex-
amination. Basic blood parameters were determined, and a skin 
prick test was carried out routinely.
For the first study cohort, 43 adult subjects (mixed gender) with 
an average age of 45 years (online suppl. Table S1, for all online 
suppl. material, see www.karger.com/doi/10.1159/000/499431) 
were recruited. 34 patients with a clinical atopic disease history 
(atopic asthma, atopic eczema, atopic rhinitis) were included. 
When different atopic symptoms were diagnosed in a single indi-
vidual, this patient was allocated to the disease group with the most 
prominent symptoms. As respective control group, 9 healthy vol-
unteers (mixed gender) who never experienced atopic episodes 
were recruited. The second cohort comprised a total of 38 indi-
viduals with an average age of 38 years, including 21 patients with 
a known atopic history and 17 healthy controls. A written in-
formed consent was obtained from each patient. The study was 
approved by the local ethics committee under the permission No. 
EA1/052/16.
Blood Withdrawal, RNA Preparation and Reverse 
Transcription
EDTA blood was obtained by venipuncture. For plasma collec-
tion blood samples were centrifuged at 4,000 g at 4  ° C for 10 min. 
The plasma layers were collected and stored at –80  ° C. RNA prep-
aration from whole blood samples was performed using a QIAamp 
RNA Blood Mini Kit (Qiagen, Hilden, Germany). cDNA synthesis 
was performed with 0.5 µg of total RNA using the RevertAidTM 
Premium First-Strand cDNA Synthesis Kit (Thermo Fischer Sci-
entific, Germany).
Quantification of Plasma Levels of IgE and IL-4
Total circulating IgE levels were determined in the Central Lab-
oratory Unit of Charité (Labor Berlin Charité Vivantes GmbH) 
using the ImmunoCAP-Test (UNICAP-250). IgE quantification 
was carried out for 27 individuals since 7 patients had previously 
received anti-IgE therapy (omalizumab). IL-4 serum levels were 
quantified employing a highly sensitive ELISA kit (IBL Interna-
tional, Hamburg, Germany), which was used according to the 
manufacturer’s instruction.
Quantitative Real-Time Polymerase Chain Reaction
To quantify the expression level of hALOX15, hALOX15B, 
hALOX12, hALOX5, human monoamine oxidase A (hMAOA) and 
fibronectin (FN) quantitative real-time polymerase chain reaction 
(qRT-PCR) was carried out on a Rotor Gene 3000 device (Corbett 
Research, Mortlake, Australia) using the SensiMixTM SYBR PCR 
Kit (Bioline, Luckenwalde, Germany). For each target gene, spe-
cific exon-spanning amplification primers (online suppl. Table S2) 
were synthesized (BioTez, Berlin, Germany). The expression of 
target genes was normalized to GAPDH expression. The n-fold 
change differences for each gene were calculated by relating the 
patient individual expression levels to the mean of gene expression 
of all samples.
Monocyte Preparation, ALOX Activity Assay and  
High-Performance Liquid Chromatography Analysis
Human peripheral monocytes were prepared from heparinized 
human blood by density step gradient centrifugation using Ficoll 
Paque (ρ = 1.077 g/mL) and adherence to plastic dishes [22]. To 
quantify their fatty acid oxygenase activity, monocytes (106 cells/
mL PBS) were incubated in vitro with arachidonic acid (100 µM) 
for 15 min at 37  ° C (assay volume 0.5 mL). The hydroperoxy fatty 
acids were reduced with sodium borohydride, and protein was 
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precipitated with 0.5 mL ice-cold methanol. Denatured protein 
was spun down, and aliquots of the clear supernatant were ana-
lyzed by reversed-phase high-performance liquid chromatogra-
phy (RP-HPLC) [22].
Statistical Evaluation of the Experimental Data
Statistical evaluation of the data was performed using the IBM 
SPSS Statistics software packages. Since most data were not nor-
mally distributed, the nonparametric Mann-Whitney U test was 
applied (cases vs. controls). When performing multiple statistical 
comparisons on the same dependent variable, a Bonferroni adjust-
ment was performed. For correlation analysis, the 2-tailed Spear-
man ρ test was carried out. p values < 0.05 were considered as sta-
tistically significant.
Results
Plasma Concentrations of IgE and IL-4 Are Elevated 
in Atopic Patients
When we quantified the IgE and IL-4 plasma con-
centrations of healthy volunteers and atopic patients, 
we found that consistent with literature reports [11, 16–
19] the circulating IgE levels (Fig. 1a) were significantly 
(p < 0.001) elevated in atopic patients (2,550 ± 833 vs. 
51 ± 18 kU/mL). A significant increase (p = 0.007) was 
also observed for plasma IL-4 levels (Fig. 1b) (0.94 ± 
0.05 vs. 0.75 ± 0.03 pg/mL). Next, we separately ana-
lyzed the total IgE (Fig. 1c) and IL-4 levels (Fig. 1d) for 
the different atopic entities and found no significant 
(p = 0.168) elevation of the IgE levels in patients with 
allergic rhinitis. In contrast, atopic eczema and atopic 
asthma patients showed significantly augmented IgE 
plasma levels (p < 0.001 for atopic eczema and p = 0.036 
for allergic asthma). For circulating IL-4 (Fig. 1d), we 
detected a significant (p < 0.001) increase in atopic asth-
ma patients. Atopic eczema (p = 0.525) and atopic rhi-
nitis patients (p = 0.336) showed no significant altera-
tions.
Expression of IL-4-Sensitive Genes in Blood 
Leukocytes
To explore whether the increased IL-4 plasma concen-
trations in atopic patients induce the expression of se-
lected IL-4-sensitive genes in peripheral leukocytes, we 
quantified the corresponding mRNAs by qRT-PCR. Here 
we did not observe significant alterations for ALOX15 but 
a statistical trend (p = 0.053) for increased ALOX15B ex-
pression (Fig.  2a). No significant differences were ob-
served for ALOX5 and ALOX12.
When we separately analyzed the different disease 





































































































































Fig. 1. Concentrations of total IgE and IL-4 in the blood plasma of 
healthy human volunteers and patients suffering from atopic dis-
eases. Comparison of total IgE (a) and IL-4 (b) plasma levels of 
healthy volunteers (n = 9) and atopic patients (n = 27 for IgE and 
n = 34 for IL-4, respectively) independent of the pathological enti-
ties. Comparison of IgE (c) and IL-4 (d) plasma levels of healthy 
volunteers (n = 9) and atopic patients separated for their patho-
logical entities (allergic rhinitis n = 11, atopic eczema n = 11, atop-
ic asthma n = 5 for IgE and n = 12 for IL-4, respectively). Statistical 
evaluation was carried out applying the nonparametric Mann-
Whitney U test with subsequent Bonferroni adjustment; p < 0.05 
was considered as statistically significant.
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fold increase in ALOX15 expression in allergic rhinitis 
(Fig. 2b). For atopic eczema patients, a similar 2.23-fold 
increase in ALOX15 expression was observed (Fig. 2b), 
but here again only borderline significance was calcu-
lated (p = 0.093). For atopic asthma patients a significant 
(p = 0.021) decrease in ALOX15 expression was ob-
served (Fig. 2b). For ALOX15B no significant alterations 
were observed for atopic eczema and atopic asthma pa-
tients (p = 0.885 and 0.930, respectively). However, we 
found a small (1.93-fold) but significant (p = 0.030) in-





























































































































































































































Fig. 2. Expression of ALOX isoforms in blood leukocytes of healthy 
human volunteers and patients suffering from atopic diseases. Ex-
pression of ALOX isoforms was determined by qRT-PCR, and the 
ratio of mRNA copies of the target gene per 1,000 copies of GAP-
DH mRNA was calculated. a Comparison of the expression of dif-
ferent ALOX-isoforms in blood leukocytes of healthy controls 
(n = 9) and pooled atopic patients (n = 34) independently of their 
pathological entities. b–d Comparison of the expression of 
ALOX15 (b), ALOX15B (c) and ALOX5 (d) in blood leukocytes of 
healthy controls (n = 9) and patients suffering from different enti-
ties of allergic diseases (allergic rhinitis n = 11, atopic eczema n = 
11, atopic asthma n = 12). Statistical evaluation was carried out 
applying the nonparametric Mann-Whitney U test with subse-
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ALOX5 and its major pro-inflammatory reaction 
product leukotriene B4 has been implicated in the patho-
genesis of bronchial asthma and other inflammatory dis-
eases, including skin inflammation [7, 23–25]. Moreover, 
an ALOX5 inhibitory activity has been shown for anti-
inflammatory medicinal plants, and pharmaceutical 
preparations of these plants have been used for the treat-
ment of inflammatory skin diseases in traditional medi-
cine [26]. These data suggested a role of ALOX5 in atop-
ic diseases and thus, we quantified expression of ALOX5 
in atopic asthma patients but did not observe significant 
differences to healthy controls (Fig. 2d). This was neither 
the case for other atopic entities (Fig. 2d). These results 
are consistent with data obtained in a previous report 
[27].
In addition to ALOX15 and ALOX15B, expression of 
FN and of MAOA is also upregulated in vitro by IL-4 
[17]. When we explored whether such expression regu-
lations can also be observed in vivo, we did not find 
any differences between atopic patients and healthy 
controls (Fig. 3a). We neither observed significant dif-
ferences for MAOA (Fig. 3b) and FN (Fig. 3c) expres-
sion when the different atopic entities were compared 
separately.
Correlation Analysis
When we correlated plasma IgE and plasma IL-4 lev-
els, we did not find a significant correlation regardless of 
whether we only included the data from atopic patients 






















































































































































Fig. 3. Expression of additional IL-4-sensitive genes (MAOA, FN) 
in blood leukocytes of healthy human volunteers and patients suf-
fering from atopic diseases. Expression of IL-4-sensitive genes was 
quantified by qRT-PCR, and the ratio of mRNA copies of the target 
gene per 1 × 106 copies of GAPDH mRNA was calculated. a Com-
parison of the expression MAOA and FN in blood leukocytes of 
healthy controls (n = 9) and pooled atopic patients (n = 34) inde-
pendently of their pathological entities. b, c Comparison of the 
expression of MAOA (b) and FN (c) in blood leukocytes of healthy 
controls (n = 9) and patients suffering from different entities of al-
lergic diseases (allergic rhinitis n = 11, atopic eczema n = 11, atop-
ic asthma n = 12). Statistical evaluation was carried out applying 
the nonparametric Mann-Whitney U test with subsequent Bonfer-
roni adjustment.
Table 1. Correlation analyses




r p r p
IgE vs. IL-4 0.351 0.072 0.131 1
IL-4 vs. ALOX15 –0.270 0.160 –0.352 0.082
IL-4 vs. ALOX15B 0.036 1 –0.083 1
ALOX15 vs. ALOX5 0.371 0.028 0.430 0.022
IL-4 vs. MAOA –0.144 0.716 –0.173 0.654
IL-4 vs. fibronectin 0.253 0.204 0.204 0.496
MAOA vs. ALOX15 –0.177 0.510 –0.292 0.188
Fibronectin vs. ALOX15 0.192 0.436 0.228 0.392
Significant results are italicized. Correlation analyses were 
carried out with the IBM SPSS Statistics software packages; the 
2-tailed Spearman ρ test was employed.
Lipoxygenase Expression in Atopy 197Skin Pharmacol Physiol 2019;32:192–200
DOI: 10.1159/000499431
Similarly, we did not observe a correlation between the 
plasma IL-4 levels and ALOX15 and ALOX15B expres-
sion (Table 1). However, we observed a significant posi-
tive correlation between the expression of ALOX15 and 
ALOX5 (Table 1). When we correlated the IL-4 plasma 
levels with MAOA or FN expression, we did not find sig-
nificant correlations, and this was also the case when we 
compared the expression of these two genes with that of 
ALOX15 (Table 1).
Fatty Acid Oxygenase Activity of Blood Monocytes
When human peripheral monocytes were cultured in 
vitro for 72 h in the presence of IL-4 (25 ng/mL), they 
exhibit a strong arachidonic acid oxygenase activity as 
indicated by HPLC analysis (Fig. 4a). In fact, the major 
oxygenation product co-chromatographed in RP-HPLC 
with an authentic standard of 15-HETE (hydroxyeico-
satetraenoic acid). Chiral-phase HPLC (inset) indicated 
the strong preponderance of 15S-HETE indicating its 
enzymatic origin. When the monocytes were cultured in 
the absence of IL-4, an unspecific product pattern was 
detected (Fig.  4b) suggesting that ALOX15 and AL-
OX15B are not expressed. This conclusion is consistent 
with qRT-PCR data for ALOX15 mRNA (0.25 copies of 
ALOX15 mRNA/103 GAPDH copies in the absence of 
IL-4 vs. 554.67 copies of ALOX15 mRNA/103 GAPDH 
copies in its presence).
When we isolated monocytes from atopic patients 
and assayed their fatty acid oxygenase activity, we found 
that the corresponding chromatograms were similar to 
those of corresponding control cells (comparable with 
Fig. 4b). For statistical evaluation we quantified the peak 
areas of the HETE region (from 6 to 10 min) but did not 
detect any significant difference between monocytes 
prepared from healthy controls and atopic patients 
(Fig. 4c).
Discussion
Role of IL-4 and ALOX Isoforms in Atopic Diseases
ALOX isoforms have been implicated in the patho-
genesis of atopic diseases [28] and cysteinyl leukotriene 
receptor antagonists (montelukast, zafirlukast) [29], 
and leukotriene biosynthesis inhibitors (zileuton) [30] 
are currently used for the treatment of bronchial asthma 
and allergic eye diseases. Moreover, the anti-inflamma-
tory activity of some medicinal plants has been related 
to their inhibitory activity of the ALOX5 pathway, and 
pharmaceutical extracts of such plants have been em-
ployed for the treatment of atopic eczema [26]. More-
over, a number of ALOX inhibitors exhibit antioxida-
tive properties, and some of them are useful chemopre-
ventive agents of oxidative stress [31, 32]. However, the 
precise roles of pro-inflammatory leukotrienes [32] and 
anti-inflammatory lipoxins/resolvins [33, 34] in atopic 
diseases are not completely understood. A recent study 
reported that patients suffering from atopic dermatitis 
show an altered profile of lipids in blood plasma [35] 
and in the skin [36] and these data have been suggested 
to point towards an increased production of ALOX-de-
rived pro-inflammatory mediator [35]. IL-4 has previ-
ously been identified as regulator of the ALOX pathway 
in monocytes/macrophages and dendritic cells [21, 22, 
37], and microarray-based expression profiles suggest-
































































Fig. 4. In vitro and ex vivo ALOX activity assays employing iso-
lated monocytes as enzyme source. a RP-HPLC analysis of ara-
chidonic acid oxygenation products formed during the in vitro 
incubation of human peripheral monocytes with arachidonic 
acid. Monocytes cultured for 72 h in the presence of 25 ng/mL 
human recombinant IL-4. Inset Enantiomer analysis of 15-HETE 
isolated by RP-HPLC. b RP-HPLC analysis of arachidonic acid 
oxygenation products formed during the in vitro incubation of 
human peripheral monocytes with arachidonic acid. Monocytes 
were cultured for 72 h in the absence of IL-4. The arachidonic 
acid oxygenation products were identified according to retention 
time of authentic standards. * Chromatographic region integrat-
ed for quantification and statistical evaluation. c Statistical evalu-
ation of HETE formation by blood monocytes prepared from 
healthy volunteers (n = 17) and patients suffering from atopic 
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ALOX15 and ALOX15B [21, 22, 37, 38]. Unfortunately, 
the in vivo relevance of this in vitro effect has not been 
tested so far. Since atopic patients have frequently in-
creased IL-4 plasma concentrations [11, 17], we hypoth-
esized increased expression levels of IL-4-sensitive 
genes in peripheral leukocytes of such patients. Al-
though we found significantly increased IgE plasma lev-
els in allergic patients (Fig. 1a), systemic IL-4 concen-
tration levels were only significantly augmented in al-
lergic asthma patients (Fig.  1b, d), and there was no 
significant correlation between the individual IgE and 
IL-4 levels. Analyzing the expression of IL-4-sensitive 
genes (ALOX15, ALOX15B, ALOX5, FN, MAOA) in 
blood leukocytes, we did not find significant differences 
between atopic patients and healthy controls (Fig.  2a 
and 3a). Thus, the increased circulating IL-4 levels, 
which are observed in some atopic entities, do not sig-
nificantly upregulate the expression of IL-4-sensitive 
genes.
Circulating IL-4 Levels Are Not High Enough to 
Induce Expression of IL-4-Sensitive Genes
To explore the possible reasons for this in vitro ver-
sus in vivo discrepancy, we compared the IL-4 concen-
trations used for induction of the in vitro effect with the 
elevated IL-4 concentrations reached in atopic disease. 
The circulating IL-4 levels in atopic patients varied be-
tween 0.7 and 2.4 pg/mL plasma but in the literature 
there is a higher degree of variation (1–500 pg/mL) [11, 
16–19]. To induce in vitro expression of IL-4-sensitive 
genes in monocytes, IL-4 concentrations between 10,000 
and 50,000 pg/mL were usually employed [21, 22, 38]. 
For other cell types (epithelial cells [39], endothelial 
cells [40], fibroblasts [41], preadipocytes [42]), IL-4 
concentrations as low as 200 pg/mL were used. Thus, 
the IL-4 concentrations employed for the in vitro ex-
periments with isolated monocytes were considerably 
higher than the in vivo concentrations detected in atop-
ic patients.
Possible Impact of Medication on IL-4-Induced 
Expression of IL-4-Sensitive Genes
Some patients enrolled in this study have previously 
received different types of antiatopic medication (online 
suppl. Table S1), and due to ethical reasons treatment was 
not interrupted. A limitation of this study is that we did 
not test whether the medication might have inhibited ex-
pression of IL-4-sensitive genes. Indeed, IL-4-dependent 
induction of ALOX15 expression in monocytes was part-
ly inhibited by high (100 nM) concentrations of hydrocor-
tisone [22]. However, hydrocortisone was not systemi-
cally applied. Thus, the possibility that antiatopic medica-
tion might have interfered with the expression of 
IL-4-sensitive genes is unlikely.
Expression of ALOX5 in Blood Leukocytes of Atopic 
Patients
Leukotrienes have been implicated in atopic diseases 
[30, 43] and ALOX5 functions as key enzyme in leukotri-
ene biosynthesis [20]. In previous reports conflicting data 
have been published on the expression of ALOX5 in pe-
ripheral leukocytes in atopic patients. In a primary study 
no significant elevation of ALOX5 expression has been 
detected in asthmatic patients [27]. In a later trial a small 
(2-fold) but significant (p < 0.05) upregulation of ALOX5 
expression in blood leukocytes of asthmatic patients was 
observed [44]. Our data are consistent with the original 
report, and insignificant differences were obtained for all 
atopic entities (Fig. 2d). The reasons for these conflicting 
results are unclear but in addition to the different inclu-
sion criteria [27, 44], methodological differences might 
contribute.
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